Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that the U.S. Food &
Drug Administration (FDA) has issued an approvable letter for the head
lice treatment. Sciele Pharma is working closely with Summers
Laboratories and the FDA to provide additional information that was
requested.
About Sciele Pharma, Inc.
Sciele Pharma, Inc. is a pharmaceutical company specializing in sales,
marketing and development of branded prescription products focused on
Cardiovascular/Diabetes, Women's Health and Pediatrics. The Company's
Cardiovascular/Diabetes products treat patients with high cholesterol,
hypertension, high triglycerides, unstable angina and Type 2 diabetes;
its Women's Health products are designed to improve the health and
well-being of women and mothers and their babies; and its Pediatrics
products treat allergies, asthma, coughs and colds, and attention
deficit/hyperactivity disorder (ADHD). Founded in 1992 and headquartered
in Atlanta, Georgia, Sciele Pharma employs more than 900 people. The
Company's success is based on placing the needs of patients first,
improving health and quality of life, and implementing its business
platform - an Entrepreneurial Spirit, Innovation, Speed of Execution,
Simplicity, and Teamwork.
About Summers Laboratories, Inc.
Summers Laboratories is a privately-held pharmaceutical company
specializing in highly-targeted prescription and non-prescription
products for pediatric and adult dermatology. Summers' leading brand is
Triple Paste(R) Medicated Ointment for diaper rash. According to IRI
data, Triple Paste is one of the fastest growing diaper rash treatments
in the U.S. Triple Paste and other Summers Labs products are carried
nationwide by the largest drugstore chains: Target, Wal-Mart and other
major retailers. In addition to the lice asphyxiating product recently
acquired by Sciele Pharma, Summers Laboratories is working on developing
licensing or acquiring niche prescription and non-prescription
dermatological products.
Safe Harbor Statement
This press release contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results to
materially differ from those described. Although the Company
believes the expectations expressed in these statements are reasonable,
it cannot promise that these expectations will turn out to be correct.
Actual results could be materially different from and worse than
expectations.
Sciele Pharma, Inc.
Joseph T. Schepers, 678-341-1401
ir@sciele.com
